Nayacure Labs

Company Overview

Snapshot

Founded in December 2010 by Shahar Cohen, MD, Nayacure Labs operates with 1–10 employees. The company holds a patent for its regenerative medicine technologies.

Business overview

Nayacure Labs is a regenerative medicine company focused on developing technologies to restore the function of failing body parts and enhance human health. The company is building a pipeline of therapeutic assets and product candidates, including artificial clots for localized drug delivery, organs on demand, and placental stem cell therapy for neurodegeneration. Its lead program aims to create personalized organs to increase availability for transplantation and reduce the need for immunosuppressant drugs, ultimately seeking to overcome immunological barriers in xenotransplantation to provide an unlimited source of humanized organs.

Company Intelligence Q&A

What is Nayacure Labs' primary focus?

Nayacure Labs is primarily focused on regenerative medicine, developing technologies to restore the function of failing body parts and enhance human health.

Who founded Nayacure Labs?

Nayacure Labs was founded by Shahar Cohen, MD, in December 2010.

What is Nayacure Labs' lead program?

Nayacure Labs' lead program involves developing personalized organs to increase availability for transplantation and reduce the need for immunosuppressant drugs following organ transplantation.

What types of therapeutic assets is Nayacure Labs developing?

Nayacure Labs is developing a pipeline of therapeutic assets and product candidates, including artificial clots for localized drug delivery, organs on demand, and placental stem cell therapy for neurodegeneration.

What is Nayacure Labs' long-term goal regarding organ transplantation?

Nayacure Labs aims to overcome the immunological barrier to xenotransplantation, providing an unlimited source of humanized organs and treating human-derived composite allografts to reduce their immunogenic burden.